Health and Fitness Health and Fitness
Wed, July 6, 2011
Tue, July 5, 2011
Mon, July 4, 2011
Sat, July 2, 2011
Fri, July 1, 2011
Thu, June 30, 2011
[ Thu, Jun 30th 2011 ] - Market Wire
KCI???NPWT????????????
Wed, June 29, 2011
Tue, June 28, 2011
Mon, June 27, 2011
Sat, June 25, 2011
Fri, June 24, 2011
Thu, June 23, 2011
Wed, June 22, 2011
Tue, June 21, 2011
Mon, June 20, 2011
Sun, June 19, 2011
Fri, June 17, 2011
Thu, June 16, 2011
Wed, June 15, 2011
Tue, June 14, 2011
[ Tue, Jun 14th 2011 ] - Market Wire
Bond Labs Reports May Results
Mon, June 13, 2011
Fri, June 10, 2011
Thu, June 9, 2011
Wed, June 8, 2011

Threshold Pharmaceuticals to Present at OneMedForum Conference


Published on 2011-06-22 03:40:37 - Market Wire
  Print publication without navigation


REDWOOD CITY, Calif.--([ BUSINESS WIRE ])--Threshold Pharmaceuticals, Inc. (Nasdaq:THLD) today announced that Dr. Barry Selick, Threshold's Chief Executive Officer is scheduled to present at the OneMedForumNY Emerging Finance Conference 2011 on Thursday, June 23, at 10:15 a.m. EST in New York City.

A live webcast of the presentation will be available under the Webcast section of the Companya�s website.

About Threshold Pharmaceuticals

Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors. This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ([ www.thresholdpharm.com ]).

Forward-Looking Statements

Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding TH-302 and its potential therapeutic uses and benefits. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to, whether Threshold's Phase 2 trial of TH-302 in patients with advanced pancreatic cancer or any others that Threshold undertakes will confirm the results of earlier trials based on smaller numbers of patients, the time and expense required to conduct such clinical trials and analyze data, Thresholda�s ability to develop a commercial formulation of TH-302 and secured adequate supplies, issues arising in the regulatory process and any unanticipated or increased side-effects observed in patients receiving TH-302. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which was filed with the Securities Exchange Commission on May 12, 2011 and is available from the SEC's website ([ www.sec.gov ]) and on our website ([ www.thresholdpharm.com ]) under the heading "Investors." We do not intend to update any forward-looking statement made in this news release.


Publication Contributing Sources